Share this article
Share this article
HOUSTON, Jan. 26, 2021 /PRNewswire/ Soliton, Inc., (Nasdaq: SOLY) ( Soliton or the Company ), a medical device company with a novel and proprietary platform technology, today announced it has entered into a collaboration with the US Navy to conduct a multi-treatment proof-of-concept clinical study to evaluate the safety, and efficacy of multiple treatments with Soliton s Rapid Acoustic Pulse (RAP) device for the improvement in the appearance of fibrotic scars. The study will be a US-based, single-center, prospective trial, examining a maximum of 25 patients. We are extremely pleased to collaborate with the US Navy and investigate the safety and efficacy of our RAP device in improving the appearance of fibrotic scars, commented Brad Hauser, Soliton CEO and President. The results from our previous proof-of-concept Keloid and Hypertrophic Scar trial were extremely encouraging, as the RAP device demonstrated reductions in both the volume o